康莱特联合NP方案治疗晚期非小细胞肺癌临床研究  

Kanglaite injection combined with NP regimen in the treatment of advanced non-small cell lung cancer(NSCLC)

作　　者：黄德波[1] 朱兆峰[1] 李梁[1] 肖宝荣[1] 

机构地区：[1]泰安市肿瘤防治院放疗三科,山东泰安271000

出　　处：《现代肿瘤医学》2013年第2期321-323,共3页Journal of Modern Oncology

摘　　要：目的:评价康莱特注射液联合NP方案(长春瑞滨联合顺铂方案)化疗对晚期非小细胞肺癌的疗效及毒副反应。方法:96例经细胞学或组织学证实的晚期非小细胞肺癌按1∶1随机分为治疗组(康莱特注射液联合NP方案化疗)48例,对照组(单纯NP方案化疗)48例。结果:治疗组有效率56.3%(27/48),对照组为47.9%(23/48),P=0.4138;治疗组KPS改善率56.3%(27/48)明显高于对照组33.3%(16/48),P=0.0125;治疗组癌痛缓解率较对照组提高(88.2%∶52.6%,P=0.0206);治疗组3-4级白细胞下降20.8%(10/48),低于对照组47.9%(23/48),P=0.0531。结论:康莱特注射液配合化疗治疗晚期非小细胞肺癌可提高生活质量,缓解癌痛,减轻化疗毒副反应,提高患者的耐受性。Objective：To evaluate the therapeutic efficacy and complication of Kanglaite injection（KI） combined with NP regimen in patients with advanced non - small cell lung cancer. Methods： Ninety - six patients with advanced NSCLC confirmed histopathologically were randomly divided into two groups （48 cases in the trial group were given KI combined with NP regimen and 48 cases in the control group with NP regimen alone）. Results： All the patients received the whole treatment. The effective rates in the trial group and the control group were 56.3% （27/48） and 47.9% （ 23/48 ）, respectively, without significant statistical difference between the two groups （ P = 0. 4138 ）. The improvement rate of KPS and remission rate of cancer - relative pain in trial group was better than that in control group（ P 〈 0.05 ）. The incidence of leukocyte decrease was lower in the trial group than that in control group（ P = 0.0531 ）. Conclusion： Chemotherapy of NP combined with KI shows benefits in the treatment of advanced NSCLC. KI could improve the quality of life and relieve cancer - relative pain in patients with NSCLC. In addition, it could decrease the adverse reaction of chemotherapy and improve the patients＂ tolerance.

关 键 词：康莱特注射液 非小细胞肺癌 化学疗法 长春瑞滨 

分 类 号：R734.2[医药卫生—肿瘤]